Class summary at a glance.

Every drug in the Dihydropyridine Calcium Channel Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 13tracked in Part D
CY24 Part D spend: $689.3Mcombined across class
Total Rx claims: 82.3M25.3M unique beneficiaries
Generic mfrs (active): 87across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Amlodipine

Brand: Katerzia · 75.9M Part D claims (CY24) · 23.4M beneficiaries · First FDA approval: 1992-07-31

19 generic mfrs 0 plans require PA

Low NADAC$0.011

→

Avg plan cost$0.906

Part D spend $515.5M 85× spread, current vs floor

Class share

75%

of class CY24 spend

View profile →

Nifedipine

Brand: Procardia · 5.9M Part D claims (CY24) · 1.8M beneficiaries · First FDA approval: 1989-09-06

13 generic mfrs 28 plans require PA

Low NADAC$0.117

→

Avg plan cost$0.203

Part D spend $146.7M 2× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Felodipine

Brand: Felopdipine · 484K Part D claims (CY24) · 151K beneficiaries · First FDA approval: 2009-03-31

9 generic mfrs 0 plans require PA

Low NADAC$0.126

→

Avg plan cost$0.133

Part D spend $14.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nisoldipine

Brand: Sular · 18K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2008-07-25

2 generic mfrs 0 plans require PA

Low NADAC$3.71

→

Avg plan cost$4.51

Part D spend $6.6M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nicardipine

Brand: CARDENE IV · 6K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 1992-01-30

18 generic mfrs 0 plans require PA

Low NADAC$1.37

→

Avg plan cost$2.66

Part D spend $3.5M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Isradipine

9K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2004-01-05

2 generic mfrs 0 plans require PA

Low NADAC$1.61

→

Avg plan cost$1.68

Part D spend $1.7M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nimodipine

Brand: Nymalize · 4K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2017-11-07

5 generic mfrs 2 plans require PA

Low NADAC$1.34

→

Avg plan cost$1.34

Part D spend $1.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Amlodipine and Atorvastatin

Brand: Caduet · — Part D claims (CY24) · First FDA approval: 2004-01-30

5 generic mfrs 0 plans require PA

Low NADAC$1.01

→

Avg plan cost$1.72

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Amlodipine and Benazepril

Brand: Lotrel · — Part D claims (CY24) · First FDA approval: 1995-03-03

5 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.094

→

Avg plan cost$1.03

Part D spend — 11× spread, current vs floor

Class share

of class CY24 spend

View profile →

Amlodipine and Olmesartan Medoxomil

Brand: Azor · — Part D claims (CY24) · First FDA approval: 2007-09-26

9 generic mfrs 0 plans require PA

Low NADAC$0.240

→

Avg plan cost$1.29

Part D spend — 5× spread, current vs floor

Class share

of class CY24 spend

View profile →

Clevidipine

Brand: Cleviprex · — Part D claims (CY24) · First FDA approval: 2008-09-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Clevipidine

Brand: Cleviprex · — Part D claims (CY24) · First FDA approval: 2008-09-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Felodipine Extended-Release Tablets

Brand: Felodipine · — Part D claims (CY24) · First FDA approval: 2019-08-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.